This study evaluated the clinical outcomes of AFTV therapy in patients with newly diagnosed GBM, focusing on its relationship with key molecular pathological markers, such as IDH mutations, p53 alterations, and Programmed Death-Ligand 1 (PD-L1) expression. Here, IDH1 is linked to glioblastoma.